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EVALUATION OF CENTRAL NEUROPATHY IN TYPE 2 DIABETES:  
CASE–CONTROL STUDY 
ABSTRACT 
Introduction: Diabetes mellitus (DM) is a global pandemic affecting almost every 
organ in the body. Peripheral nervous system involvement in diabetes is well known 
but there are not much studies on central nervous system involvement. Visual evoked 
potential(VEP) is a sensitive, non invasive test to detect central demyelination of optic 
nerve. 
Aims: To compare the visual evoked potentials in type-2 DM patients with that of 
healthy controls and to find out if any correlation is there with the duration or 
glycemic control of the disease . 
Materials and methods:  We included 50 DM patients and 50 age and sex matched 
controls. Patients with previous stroke, demyelination, diabetic retinopathy and other 
opthalmological disorders were excluded. VEP was recorded using pattern reversal 
stimulation with EMG RMS MARK II machine and p100 latency was measured. 
Results: P100 latencies (ms) was significantly prolonged in diabetics with mean ± SD 
of       (111.24 ±5.28 ms) as compared to controls (101.30 ± 1.66 ms) with p value 
<0.003. Also there was significant correlation between duration of DM and P100 
latency prolongation but no significant correlation was present between glycemic 
control of patients and P100 latency. 
Conclusion: Abnormal VEP may be due to structural damage to myelinated optic 
nerve fibres or retinal ganglion cells and it occurs even before development of 
retinopathy. Hence VEP can be a used as an early marker for central neuropathy and 
offers an opportunity for early management. 
INTRODUCTION 
Diabetes mellitus (DM) is a global pandemic affecting almost 
every organ in the body. It causes serious challenge to healthcare system. 
Nearly 150 million people throughout the world are affected and the 
incidence increases with time as sedentary lifestyle and obesity is on the 
rise. Major complications of DM are due to atherosclerosis and it can 
affect any organ in body especially eyes, peripheral nerves, kidney and 
heart. These are categorized into microvascular and macrovascular 
complications. 
Diabetic peripheral neuropathy is a major public health burden. It 
is characterized by burning sensation of feet, distal weakness and absent 
deep tendon reflexes especially ankle jerk. Only 15% of DM have 
peripheral neuropathy clinically but upto 50% have peripheral neuropathy 
by nerve conduction studies. Similarly only 10% have peripheral 
neuropathy at time of diagnosis of DM but nearly 50% have neuropathy 
after 25 years duration. Duration of DM and glycemic control of DM are 
important factor for development of peripheral neuropathy.
(1)
 
 Various forms of peripheral neuropathy are known to occur in 
DM. The most common type is distal symmetric sensory polyneuropathy. 
Cranial neuropathies affecting oculomotor nerve, abducens nerve are also 
known to occur. Rarely asymmetrical, painful proximal muscle weakness 
due to diabetic amyotrophy can occur. Only 0.6% of diabetic patients 
have optic nerve involvement resulting in optic atrophy.
(2)
 
The peripheral nervous system involvement in DM has been 
studied extensively in various studies but central nervous system 
involvement in DM has not been studied in detail. The term “central 
neuropathy” has been unknown until recently. Only after few western 
studies described subclinical optic nerve involvement in DM by 
electrophysiological studies the term central neuropathy was recognized. 
Just like subclinical peripheral neuropathy, asymptomatic optic 
neuropathy or central neuropathy can occur and it is evaluated by visual 
evoked potentials. Although in diabetics the most common cause for 
blindness is diabetic retinopathy asymptomatic optic nerve dysfunction 
can occur as proved in various studies. 
Visual evoked potential (VEP) is a non invasive, sensitive tool 
which measures the impulse conducted along the central nervous 
pathway. VEP measures the P100 latency which reflects the functional 
abnormalities of optic pathway even in early stages. We decided to 
evaluate the central neuropathy in DM patients and compare with 
controls. Although there were few similar studies in past most of them 
were in western literature and sample size were small. Hence we included 
larger sample size of 100 and we also compared the latency prolongation 
with duration of DM, glycemic control and peripheral neuropathy. 
 
 
 
AIMS AND OBJECTIVES 
1. To compare the visual evoked potentials in type-2 Diabetes 
mellitus patients with that of healthy controls. 
 
2. To find out if there is any correlation with duration of DM or 
glycemic control of Diabetes with P100 latency. 
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
 Diabetes mellitus (DM) is an metabolic disorder due to decreased 
insulin secretion or action or both resulting in hyperglycemia. It is one of 
the leading cause for blindness in world. It accounts for 30% of 
preventable blindness. The global prevalence of DM is 6.6% in 2010. As 
per international diabetes federation of 285 million diabetic subjects in 
world, 70 % live in low income countries like India. India is the diabetic 
capital of the world with 57 million people suffering as per 2010 data. If 
no drastic steps are taken to stop this epidemic it is expected to further 
increase in prevalence. 
RISK FACTORS 
1. Familial aggregation 
2. Age 
3. Adiposity 
4. Body fat percentage 
5. Insulin resistance 
6. Life style changes due to urbanization 
7. High prevalence of prediabetic condition 
CHRONIC COMPLICATIONS OF DIABETES 
  Generally the injurious effects of DM are classified into 
microvascular and macrovascular complications.
(3)
 
MICROVASCULAR COMPLICATIONS 
1. Diabetic retinopathy 
2. Diabetic nephropathy 
3. Diabetic neuropathy 
MACROVASCULAR COMPLICATIONS 
1. Coronary artery disease 
2. Cerebrovascular disease 
3. Peripheral vascular disease 
PATHOPHYSIOLOGY OF COMPLICATIONS 
 Although the precise mechanism for microvascular complications 
are not known it is generally believed that there are 3 pathways which are 
involved in development of these complications. It is related to both 
duration of DM and poor glycemic control of disease. 
 The central pathological mechanism in macrovascular disease is 
atherosclerosis. Atherosclerosis occurs in response to oxidization of LDL 
cholesterol resulting in endothelial injury and inflammation. Diabetes 
enhances the effect of other co-morbid conditions like hypertension, 
dyslipidemia, smoking and obesity. In addition there is also platelet 
adhesion, plasminogen activator inhibitor and increased free radical 
generation. All these factors collectively produce a state of 
hypercoagulability. 
PATHWAYS INVOLVED: 
1. Polyol pathway 
2. AGE Pathway 
3. Protein kinase C 
POLYOL PATHWAY 
 In DM the excess glucose is shunted to aldose reductase pathway 
which results in sorbitol. Sorbitol is further metabolized to fructose. 
Neither sorbitol nor fructose can move out of the cell and it can result in 
cellular swelling. There is also depletion of myoinositol, loss of Na/K 
ATPase activity and NADPH co-factors. Hence the metabolically 
compromised axons are susceptible to injury and ischemia. The small 
thinly myelinated fibers are more affected than large fibers and hence 
sensory symptoms precedes development of motor neuropathy in DM.
(3)
 
ADVANCED GLYCATION END PRODUCTS 
 Glycation of macromolecules in diabetes results in advance 
glycosylated end products. AGE are large aggregates and cannot be 
cleared by normal metabolism. They are susceptible to oxidation and 
resulting in oxidative damage. There is a very strong association between 
AGE and development of diabetic nephropathy. AGE is a complex series 
of poorly understood reactions in DM which results in endothelial 
dysfunction.
(4)
 
PROTEIN KINASE C PATHWAY: 
   Chronic hyperglycemia in DM can stimulate protein kinase c 
pathway which mainly functions to alter vascular permeability, cellular 
proliferation and blood flow. Activation of this pathway leads to increase 
in VEGF and increased angiogenesis. This pathway has strong 
association with diabetic retinopathy.
(5)
 
DIABETIC RETINOPATHY: 
 It is the most common microvascular complication of diabetes. It 
can even precede diagnosis of diabetes mellitus.
(6)
It is related to duration 
of diabetes and degree of hyperglycemia like most of the other 
microvascular complications. It is classified as proliferative and non 
proliferative diabetic retinopathy. The aldose reductase pathway and 
accumulation of AGE have been implicated in development of diabetic 
retinopathy.
(7)  
In addition to blindness, diabetic retinopathy indicated end 
organ damage in a patient. Blindness in DM can be due to
 
1. Diabetic maculopathy due to ischemia or vitreo-macular traction 
2. Proliferative diabetic retinopathy leading to vitreous hemorrhage or 
retinal detachment 
3. Neovascular glaucoma 
4. CRAO/CRVO ( Central retinal artery/vein occlusion) 
5. Ischaemic optic neuropathy 
Strict diabetic control, regular ophthalmological evaluation and laser 
photocoagulation can prevent blindness due to diabetic retinopathy.  
CLASSIFICATION OF DIABETIC RETINOPATHY: 
1. Nonproliferative (background) retinopathy 
a. Simple background retinopathy 
b. Dot and blot hemorrhages 
c. Hard exudates 
d. Microaneurysms 
e. Macular edema 
2. Prepoliferative retinopathy 
a. Soft exudates 
b. Intraretinal microvascular abnormalities (IRMA) 
3. Proliferative retinopathy 
a. Neovascularization of the disc 
b. Neovascularization elsewhere in the retina 
c. Fibrovascular proliferation 
d. Vitreous hemorrhage 
  
 
  
DIABETIC NEUROPATHY: 
 Diabetic neuropathy is a common microvascular complication 
occurring in genetically predisposed individuals in addition to longer 
duration of DM and poor glycemic control.
(8) 
Recently there is association 
between sensory neuropathy and impaired fasting glucose without overt 
diabetes and persistent hyperglycemia with elevated HbA1c. 
 Both cranial and peripheral mono neuropathies which are of acute 
onset are mainly due to vasculopathy of ischemic origin. Pathologically 
there is ischemia of vasovasorum. The symmetrical distal polyneuropathy 
do not have evidence of vasculopathy. Hence alternative theory by Dyck 
proposed inflammation as possible cause. They found severe perivascular 
inflammation along nerve fascicles.
(1)
 
 
 
 
 
 
 
  
CLASSIFICATION OF DIABETIC NEUROPATHY 
 
 
 
  
CLINICAL FEATURES OF DIABETIC NEUROPATHY: 
 
 
VISUAL EVOKED POTENTIAL (VEP):  
 VEPS are recorded from scalp as potential differences like EEG 
(electroencephalogram) in response to some visual stimuli. It checks the 
entire visual pathway and any lesion along the visual path can produce 
abnormal VEP. Its role in localization of lesion along visual pathway is 
only limited.
(9) 
But it is very sensitive and reproducible test which can 
detect even subtle conduction defects in anterior visual pathway. 
ANATOMICAL BASIS FOR VEP 
 The two optic nerves extends from retina to optic chiasm. Each 
optic nerve is about 5cm in length. At chiasm the temporal fibers remain 
uncrossed whereas the nasal fibers cross over and extend further as optic 
tract. They relay in lateral geniculate body of thalamus and from which 
arises optic radiation. The optic radiations terminates in striate occipital 
cortex (area 17). 
 Following activation of striate visual cortex, P100 waveform in 
VEP is generated. It primarily reflects the central field that is relayed to 
area 17. Peripheral retinal stimulation does not generate P100 waveform. 
The macular fibers which is responsible for central vision occupies large 
area in occipital cortex. 
RECORDING VEPs: 
 Patient should be explained about the test and asked to sit 
comfortably in front of PC. Standard EEG electrodes are used for 
recording after degreasing the scalp. Electrodes Cz, Fz and Oz electrodes 
are placed as per 10-20 international system. Oz is active, Fz is reference 
and Cz is ground electrode. 
1. Pattern shift VEP 
2. LED goggles 
In PSVEP black and white checks are displayed in PC and patient is 
instructed to look at center of checkerboard. Patient sits 100 cm from 
screen. Impedance is kept less than 5 kΩ. Average of about 100 epochs 
are taken so that VEP results can be reproduced. 
VEP ABNORMALITIES 
There are 3 types of abnormalities in VEP 
1. Latency prolongation 
2. Amplitude reduction 
3. Both 
RECORDING VEPs: 
 
Fig 1: The patient is asked to fix his eye at the centre of the 
checkerboard which is flashed on front in a PC screen at a distance of        
100 cms. 
The commonest cause for P100 prolongation is demyelination of 
optic nerve. Unilateral P100 prolongation is likely prechiasmal lesion 
whereas bilateral P100 prolongation cannot be localized. 
VARIABLES INFLUENCING VEP 
1. AGE:  As the age increases P100 latency prolongs due to age 
related changes. It was found that approximately 2.5ms 
prolongation occurs for every decade. 
 
2. GENDER:  Males have longer latency compared to females 
probably because of larger head and hormonal differences. 
 
3. EYE MOVEMENT: Nystagmus, eye movements alter amplitude 
but not latency of P100. 
 
4. EYE DOMINANCE: P100 latency is prolonged for non dominant 
eye compared to dominant eye. 
 
5. VISUAL ACUITY: Only amplitude of P100 is affected with poor 
visual acuity and not latency. 
6. DRUGS: When miotics are used for pupillary constriction they 
decrease the area of retinal stimulation and cause P100 latency 
prolongation. The opposite effect is seen with mydriatics. 
7. MENTAL ACTIVITY: Arithmetic calculation can increase 
amplitude of P100 and decrease latency.
(10)
 
CLINICAL APPLICATIONS OF VEP 
1. DEMYELINATING DISEASES: 
 VEP is useful investigation in evaluation of multiple sclerosis. In 
patients with history of optic neuritis more than 90% have abnormal P100 
latency prolongation. It is more sensitive than MRI in detecting 
abnormalities in optic pathway. Only 84% of symptomatic patients with 
MS show abnormalities in MRI. It can detect subclinical demyelinating 
plaque.
(11) 
 
2. OPTIC NEURITIS: 
Typical optic neuritis is characterized by painful monocular vision 
loss usually occurring between 20 to 50 years of age. It is difficult to 
predict which of these patients with typical optic neuritis will develop MS 
later. Those with recurrent episodes and with typical MRI abnormalities 
have increased risk for developing MS.
(12) 
 
  
3. ISCHAEMIC OPTIC NEUROPATHY:  
It is characterized by painless loss of vision usually occurring in 
elderly patients with vascular risk factors like DM and hypertension. It 
can also occur in vasculitis and giant cell arteritis. There may be 
altitudinal field defects. VEP study shows prolongation of P100 and 
decrease in amplitude.
(13) 
 
4. TOXIC OPTIC NEUROPATHY:  
Some of toxins which can produce optic neuropathy and blindness 
are as follows 
 Tobacco 
 Alcohol 
 Ethambutol 
 Vigabatrin 
 Amiodarone 
can cause prolongation of P100 and decrease in amplitude in both 
eyes.
(14,15)
 
5. NUTRITIONAL OPTIC NEUROPATHY:  
Vitamin B12, vitamin E and thiamine deficiency can cause 
bilateral prolonged P100 latency.
(16) 
 
6. HEREDITARY AND DEGENERATIVE DISEASES:  
Following neurodegenerative conditions can produce VEP 
abnormalities 
 Friedrich ataxia 
 Charcot Marie-Tooth disease 
 Lebers hereditary optic atrophy 
 Mitochondrial disease 
           Bilateral P100 prolongation is seen with normal amplitude. P100       
prolongation  usually correlates well with temporal pallor of disc.
(17)  
 
7. COMPRESSIVE LESIONS IN VISUAL PATHWAY:   
Following lesions can compress the optic pathway 
 Meningioma 
 Tuberculoma 
 Glioma 
 Pituitary macroadenoma 
 Craniopharyngioma 
The extrinsic compression of optic pathway leads to P100 
prolongation with drop in amplitude and distortion of wave. 
 
  
8. CORTICAL BLINDNESS:  
Cortical blindness due to bilateral lesion in primary visual cortex 
can produce P100 prolongation whereas bilateral lesion in visual 
association area with preserved primary visual cortex does not produce 
abnormality in VEP.
(18)
 
 
9. MALINGERING:  
VEP is very helpful in detecting hysterical blindness. A normal 
VEP in a patient complaining of blindness gives clue to diagnosis of 
malingering. But some patients can suppress VEP and cause P100 
prolongation voluntarily. 
 
 
10. INTRAOPERATIVE MONITORING:  
VEP can be used intraoperatively while resecting tumors of optic 
pathway but has only limited role because of technical difficulties to 
provide proper illumination. 
VEP RESULTS SHOWING P100: 
 
Ziegler et al in their study included 12 diabetic patients both type 1 
and type 2. They subjected all patients to VEP and found that diabetic 
patients had P100 prolongation more than that of controls. The mean 
increase in P100 latency was 116.8+/- 4.5 with a p value <0.01. They 
treated the patients with continuous insulin infusion for a short period of 
3 days. After 3 days of intensive blood sugar control VEP was repeated 
and they found that although P100 latency was slightly prolonged 
compared to controls there was significant reduction in latency compared 
to previous value. They concluded that P100 prolongation in diabetic 
patients were probably due to impaired glucose metabolism and is 
reversible with intensive glucose control for a short period.
(19)
 
Dolu H et al studied electrophysiological characteristics of 51 
patients with type 2 DM and compared with 30 age and sex matched 
controls. They did VEP, BAEP (brainstem auditory evoked potentials) 
and SEP (somatosensory evoked potentials) for all patients. The 
multimodal evoked potential which included VEP, BAEP and SEP were 
useful in evaluating central neuropathy. They concluded that there was 
significant latency prolongation suggestive of central neuropathy in 
diabetic patients compared to controls. They did subgroup analysis and 
found that latency prolongation in SEP, VEP, BAEP correlated well with 
duration of diabetes and not with glycemic control of disease.
(20)
 
Comi G et al also studied multimodal evoked potentials in type 2 
diabetes patients using VEP, BAEP and SEP. They found that central 
neuropathy due to cortical latency prolongation was more common in 
diabetic patients with peripheral neuropathy. Isolated abnormalities in 
VEP or BAEP or SEP was more common than all three getting affected 
together. They concluded that central neuropathy may occur due to 
hyperglycemia or hypoglycemia but exact cause is not known.
(21)
 
Algan et al studied VEP in 50 type 1 diabetes and 19 type 2 
diabetes. They found significant prolongation of P100 in diabetic patients 
with p value less than 0.001. But on further analysis they concluded that 
P100 prolongation did not correlate with duration of DM or glycemic 
control of disease. Their findings were contradictory to previous 
studies.
(22)
 
Szabela DA et al studied 41 patients with type 2 diabetes. They 
recorded VEP in all patients and found 22% had abnormal P100 
prolongation. They further analysed age, duration of DM and metabolic 
control of DM with P100 latency prolongation and concluded that there 
was no correlation with either of them.
(23)
 
Again   Szabela DA et al studied 50 patients with type 1 diabetes. 
They recorded VEP in all patients and found 26% had abnormal P100 
prolongation. They further analysed age, duration of DM and metabolic 
control of DM with P100 latency prolongation and concluded that there 
was no correlation with either of them.
(24)
 
Azal O et al studied 20 diabetic patients of which 6 were type1 and 
remaining 14 were type 2. They recorded VEP in all cases and found 
significant increase in P100 latency in diabetic patients with p value 
<0.001. 45% of cases had P100 prolongation. They did not find any 
correlation with metabolic control of DM or peripheral neuropathy. They 
concluded that P100 prolongation correlated well with duration of DM.
(25)
 
Mariani E et al conducted a case control study which included 35 
diabetic patients both type 1 and type2. They recorded VEP for all cases 
and controls. They found significant prolongation of P100 latency in 
cases compared to controls. They also concluded that P100 latency 
prolongation correlated well with duration of DM, HbA1c and presence 
of peripheral neuropathy.
(26)
 
K Puvanendran et al studied 16 diabetic patients with VEP. They 
found 81% of cases had prolonged P100 latency compared to controls. 
They further analysed P100 latency with duration of DM and glycemic 
control of DM and found no significant correlation existed between them. 
They concluded that P100 latency prolongation correlated well with 
presence of diabetic sensory neuropathy.
(27)
 
Yaltkaya K et al studied 25 cases of DM and controls. VEP was 
done to measure P100, N90 and N140. Sural nerve conduction studies 
were done to detect peripheral neuropathy. They found significant P100 
and N90-140 interpeak latency prolongation. The latency prolongation 
correlated well with duration of DM but not with sural nerve conduction 
studies.
(28)
 
MATERIALS AND METHODS 
  We conducted a prospective case control study in department of 
neurology PSG institute of medical science and research from October 
2011 to October 2013. Patients were chosen from neurology OPD. 
INCLUSION CRITERIA 
Newly diagnosed type 2 Diabetes mellitus and known case of DM were 
included 
WHO criteria was used for diagnosing DM; 
1. Random plasma glucose of  > 11.1 mmol/l  
or 
2. Fasting plasma glucose > 7.0 mmol/l  
or 
3. Two hour plasma glucose concentration > 11.1 mmol/l two hours 
after 75g anhydrous glucose in an oral glucose tolerance test 
(OGTT).
(29)
 
EXCLUSION CRITERIA 
1. Patients with long standing history of hypertension and with the 
past history of cerebrovascular accident.  
2. Evidence of optic atrophy  
3. Past history of optic neuritis 
4. Visual acuity less than 6/18 
5. Patients consuming > 100 ml of alcohol daily. 
6. Patients with peripheral nervous system disease unrelated to 
diabetes mellitus. 
7. Patients with diabetic retinopathy, cataract, glaucoma and vitreous 
hemorrhage. 
8. Patients with type 1 diabetes mellitus. 
 
CONSENT: Informed consent was obtained from patients who were 
willing to take part in the study. Ethical committee clearance was 
obtained. 
METHODOLOGY: 
50 diabetic patients who fulfilled the inclusion criteria were chosen 
and 50 age and sex matched controls were also included. They were 
subjected to detailed history to rule out stroke, past history of optic 
neuritis and other ophthalmological conditions. Detailed clinical 
examination, peripheral nervous system examination and 
ophthalmological evaluation including visual acuity, fundus examination 
was performed in all subjects. Later all patients were subjected to visual 
evoked potential test. 
RECORDING TECHNIQUE: 
VEPS were recorded using RMS EMG EP mark 2 machine with 2 
channel and routine silver chloride disc electrodes. The PC based RMS 
machine was used and pattern reversal method was followed to record 
P100 latency. Before undergoing VEP, patient were instructed not to 
apply oil to head and take a shampoo bath. This is to decrease the 
impedance to less than 5Ω. They were advised not to use any mydriatics 
or meiotic 12 hours prior to VEP. If they use spectacles for refractory 
error they must continue to wear it during test. VEP is recorded in dark 
and quiet room. Patient sits comfortably in front of PC screen. Gentle 
cleaning of scalp is done before applying electrodes using spirit. Cz, Fz 
and Oz electrodes were used. Oz was active, Fz as reference and Cz was 
ground electrode. Fz is 12 cm above inion in frontal region, Cz in cetral 
area and Oz in posterior head region as per international 10-20 system. 
The patient is asked to fix his eye at the centre of the checkerboard 
with checker of size 8*8cm which is flashed on front in a PC screen. The 
distance between the PC screen and the subject was kept at a constant 
distance of 100 cms. The aim was to achieve maximum stimulation of 
foveal and parafoveal fibers at 75% contrast and a reversal rate of 1.2 Hz. 
Uniocular stimulation was given separately for both eyes with white and 
black checks and the potential is recorded in wave form in a computer. 
VEP measurement normally produces a series of waveforms in PC which 
have negative and a positive component. The negative is N wave and 
positive is takes as P wave. The parameters usually recorded are P100, 
N70 and N155. Of these P100 is most important and it indicates latency 
of positive wave. They were measured in microvolts. Statistical analysis 
was done and p value was determined. 
1. p > 0.05 (non significant) 
2. p < 0.05 (significant) 
3. p < 0.001 (highly significant) 
  
WAVES IN VEP: 
 
FIG 2: The time taken in milliseconds is marked in x-axis and the evoked 
potentials in microvolt are marked in y-axis. A graph is obtained with a 
positive peak PI00 and two negative peaks N70 and N155. The latency of 
P100 value is obtained and analyzed. 
POSITIONING OF ELECTRODES 
 
FIG 3:  Oz -active, Fz -reference and Cz- ground electrode 
 
 
 
POSITIONING OF ELECTRODES 
 
FIG 4: Shows 10 – 20 international system for electrode placemen 
 
 
OBSERVATION AND RESULTS 
AGE DISTRIBUTION 
 
CHART-1: Shows 24 patients between 50 to 60 yrs, 7 patients between 
40 to 50 years and 19 more than 60 yrs 
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SEX DISTRIBUTION 
 
CHART-2: Shows 21 females and 29 males in study group 
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CHART-3:  Among 7 cases in 40 -50 years group 5 had prolonged P100. 
In 50 -60 years group 18 had abnormal P100 and 6 had normal value. 
Above 60 years all except one had abnormal P100 
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CHART-4: Among 29 males 25 had prolonged P100 and 4 had normal 
value. In females 16 had P100 prolongation and 5 had normal P100. 
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CHART-5: Among 50 cases 41 had prolonged P100 and 9 had normal 
P100 whereas in controls only one had prolonged P100 and rest 49 had 
normal P100 
 
 
 
 
P100 VS HbA1c 
 
 
 
 
 
 
 
 
 
P100 VS HbA1c 
 
CHART-6: Among 20 cases with well controlled DM 15 had P100 
prolongation and 5 had normal P100, whereas among those with 
uncontrolled DM 26 had prolonged P100 
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P100 VS DURATION 
 
CHART-7: Among those with DM of less than 5 years 8 had normal 
P100 and 12 had abnormal value, whereas cases with DM more than 10 
years all 20 patients had abnormal prolonged P100 
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P100 VS PNP 
 
CHART-8: Among cases with PNP 23 had prolonged P100 and 3 had 
normal P100 whereas those without PNP 18 had prolonged P100 and 6 
had normal value. 
 
 
 
DISCUSSION 
 We had 50 cases of diabetes patients who fulfilled the inclusion 
criteria after vigorously excluding many patients by history, clinical and 
ophthalmological examination. VEP was done in these 50 patients as 
well as 50 age and sex matched controls. In VEP there were one positive 
peak (P100) and two negative peaks (N 70 AND N155). P100 is 
produced by occipital striate cortex in response to stimulation of visual 
cortex. P100 is the most prominent wave among all three and is easily 
reproducible without much variation in an individual. The most ideal 
parameter in VEP is latency as amplitude has greater variability and is 
less reliable. Hence we measured P100 latency for all patients. 
 The mean age our population was 58.44. There were 29 males and 
21 females. 7 cases were 40 to 50 years old, 24 between 50 to 60 years 
and 19 more than 60 years. In our study P100 latencies (ms) was 
significantly prolonged in diabetics with mean ± SD of (111.24 ± 5.28 
ms) as compared to controls (101.30 ± 1.66 ms) with p value <0.003. 
Among 50 cases 41 cases had prolonged P100 latency when compared to 
controls only one had P100 prolongation which was statistically very 
significant. Hence 81% of diabetic patients in our cases had central 
neuropathy. We also noted that mean prolongation of P100 in cases was 
much more than in controls. 
 We further divided the cases into two groups. Those with 
uncontrolled DM with HbA1c > 7 and those with well controlled DM 
with HbA1c < 7. Among the 30 cases in uncontrolled group 26 had P100 
prolongation and in 20 cases in well controlled group 15 had prolonged 
P100 latency. 75% of well controlled group and 86% of uncontrolled 
group had P100 prolongation. There was no statistically significant 
correlation between the two groups as p value was 0.293. Similarly we 
looked into duration of DM and classified the cases into 3 groups as <5 
years, 5 to 10 years and > 10 years. Among the 20 cases in <5 years 
group 12 had abnormal P100 and in 5 to 10 year group 9 out of 10 had 
abnormal P100. In > 10 year group all 20 had prolongation of P100 
which was statistically significant (p value <0.03). Hence we noted 
100% of cases with >10 year DM had abnormal VEP whereas only 60 % 
had prolonged P100 in <5 year group. 
 We also analysed age of patients with P100 latency. We found that 
5 out of 7 cases in 40 to 50 year group had abnormal P100. Likewise 18 
out of 24 cases in 50 to 60 year group and 18 out of 19 cases in more 
than 60 year group had prolongation of P100. 71 % of cases between 40 
to 50 years, 75 % of cases in 50 to 60 year group and 94 % in more than 
60 years group had central neuropathy. There was no statistical 
significance between age and central neuropathy. We also evaluated 
peripheral neuropathy (PNP) with central neuropathy and classified the 
cases into those with PNP and without PNP. Among 24 cases without 
PNP 18 had prolonged P100 and 23 out of 26 had abnormal P100 in PNP 
group. 75 % and 94 % of cases had prolonged P100 in the above groups. 
There was no statistical significance and we found central neuropathy 
occurring in almost equal percentage in patients with or without PNP. 
 Similar to our study Dolu H et al, Azal O et al, Szabela D et al, Li 
P et al, Algan et al, and Comi G et al also concluded prolongation of 
P100 in diabetic population in their studies. 
(20,25,23)
 But Szabela D et al 
and Algan et al concluded there was no correlation between duration of 
DM and P100 prolongation.
(22)
 Ziegler et al and Li P et al summarized 
that P100 prolongation correlated well with glycemic control of DM and 
even improved with short term glycemic control. 
(19)
 We believe that 
since the sample size was small in most studies and they also included 
both type 1 and type 2 DM it produced varying results. Moreover in our 
study 81% of cases had prolonged P100 whereas only 58%, 28 % and 
33% of cases had P100 latency abnormality in above studies. In spite of 
our strict exclusion criteria we produced the maximum percentage of 
P100 prolongation.           We also believe that inclusion and exclusion 
criteria varied significantly between each studies resulting in varying 
percentage of abnormalities in VEP. Our study and Dolu H et al 
conclude that central neuropathy in DM correlates well with duration of 
DM and not glycemic control. 
 At present the significance of P100 prolongation in diabetic 
patients is not known. It may be due to functional disturbance in visual 
conduction pathway rather than demyelination or axonal loss. It is also 
possible that early diabetic preretinopathy due to retinal ganglion cell 
loss may also contribute to P100 prolongation. Exact pathophysiology 
for central neuropathy is not known. We suggest it may be multifactorial 
like PNP both metabolic and vascular factors playing a role. 
Accumulation of neuropoietic cytokines like TNF-alpha, TGF-beta in 
visual conduction pathway probably causes delay in P100 latency. As 
duration of DM increases further accumulation of mediators cause 
further P100 prolongation. 
 
 
SUMMARY 
 The mean age our population was 58.44 
 The  P100 latencies (ms) was significantly prolonged in diabetics 
with mean ± SD of (111.24 ± 5.28 ms) as compared to controls 
(101.30 ± 1.66 ms) with p value <0.003. 
 In our study 81% of diabetic patients in our cases had central 
neuropathy as evidenced by prolonged P100 latency. 
 In cases with DM > 10 years had prolongation of P100 which was 
statistically significant (p value <0.03). 
 There was no statistically significant correlation between P100 and 
HbA1c or age of patients. 
  75 % of cases without PNP had prolonged P100 and 94 % of cases 
with PNP had prolonged P100. Although there was no statistical 
significance, central neuropathy can occur even before PNP. 
 
 
 
LIMITATIONS 
 Although our sample size is largest when compared to other similar 
studies we suggest still larger samples are required to validate the 
findings in our study. 
 
 Many of type 2 DM patients who were above 60 years may have 
age related changes unrelated to DM causing prolonged P100.  
 
 
 
 
 
 
 
 
 
 
  
CONCLUSION 
 Central neuropathy as measured by P100 latency is very common 
in type 2 DM. 
 Similar to subclinical sensory neuropathy which is detected in 
majority of DM by nerve conduction studies, subclinical central 
neuropathy in DM can be detected by VEP. 
 It is related to duration of DM and not HbA1c unlike PNP which is 
related to both. 
 Central neuropathy occurs even prior to development of 
retinopathy or PNP. 
 VEP is a non invasive and sensitive screening tool to detect early 
neurological involvement in DM.   
 Since there is a very high incidence of P100 prolongation in DM 
patients its usefulness in evaluation of multiple sclerosis in a 
diabetic patient may be limited. 
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PROFORMA 
NAME              : 
AGE                 : 
SEX                   : 
OCCUPATION  : 
IP NO/OP NO: 
1.   Do you have Diabetes? If yes, how long and treatment details? 
2.   Do you have Hypertension? If yes, how long and treatment details? 
3.   Do you smoke? If yes, how much per day? 
4.   Do you drink alcohol? If yes, how much per week? 
5.   Did you have previous attack of stroke? 
6.   Did you have previous eye problems? If yes, details of it? 
7.   Clinical peripheral neuropathy – yes or no 
8.   HbA1c – 
9.   Fundus – 
10. VEP –P100 – 
 
  
PSG INSTITIUTE OF MEDICAL SCIENCES AND RESEARCH, Coimbatore 
Institutional Human Ethics Committee 
INFORMED CONSENT 
I, Dr. E. PRASANNA VENKATESAN, postgraduate from the department of 
Neurology of  PSG Institiute Of Medical Sciences And Research (PSG IMS&R), am 
carrying out a study on topic, “EVALUATION OF CENTRAL NEUROPATHY IN 
TYPE 2 DIABETES CASE –CONTROL STUDY” to under the aegis of the 
Department of Neurology, PSG IMS&R. 
The objectives of this study are:  
 To compare the visual evoked potentials in type-2 Diabetes mellitus patients 
with that of healthy controls. 
 To find out if there is any correlation with duration of DM or glycemic 
control of Diabetes with P100 latency.  
Sample size: 100 
Respondents are patients with type 2 diabetes attending neurology OPD. 
Consent:  The above information regarding the study, has been read by me/read to me, 
and has been explained to me by the investigator/s. Having understood the same, I 
hereby give my consent to them to interview me and undergo VEP. I am affixing my 
signature/left thumb impression to indicate my consent and willingness to participate 
in this study. 
 
Signature/left thumb impression of the study volunteer/legal representative:  
 
Signature of the interviewer with date:                               Witness: 
  
 

 
 
 MASTER CHART 
CASES 
S.NO 
PATIENTS 
NAME 
AGE SEX HBA1C DURATION 
RIGHT     
P100 
LEFT 
P100 
PNP 
1 Si 58 M 9.2 20 115 114 YES 
2 Ra 60 M 12.2 7 104 105 YES 
3 Amu 50 F 7.3 3 102 101 NO 
4 Ra 51 F 9.3 1 105 104 NO 
5 Me 56 M 6.7 7 118 117 NO 
6 Sh 55 F 8.3 1 106 104 NO 
7 Vi 62 M 6.6 3 104 105 NO 
8 Ku 64 M 7.5 1 110 111 NO 
9 Na 51 M 6.9 3 112 111 YES 
10 Ra 42 M 6.6 1 103 104 NO 
11 Sh 53 M 10.1 2 112 111 YES 
12 Dh 60 F 9.6 7 115 114 NO 
13 Ku 53 F 7.1 2 106 107 NO 
14 Po 57 M 7.8 10 118 117 YES 
15 Am 65 F 10.1 5 111 110 YES 
16 Fa 61 F 11.1 10 120 119 YES 
17 Ka 50 F 7.6 10 116 117 NO 
18 Ve 60 F 6.1 2 105 104 YES 
19 Sg 64 M 10.1 10 116 116 YES 
20 Je 60 M 6.2 11 120 119 NO 
21 Su 70 M 7 12 116 115 YES 
22 Sm 70 F 7.1 5 110 109 NO 
23 Vl 52 F 11.3 13 112 113 NO 
24 Gv 65 M 7.9 3 110 109 YES 
 25 Rd 50 F 9.9 1 108 109 YES 
26 Rg 60 M 14.4 1 106 107 YES 
27 Ka 66 F 8.6 11 120 119 YES 
28 Jl 57 M 9.9 15 119 120 YES 
29 Sd 60 M 8.4 3 100 99 YES 
30 Ar 66 M 10.1 30 118 117 YES 
31 Ml 53 F 8.5 11 119 119 YES 
32 Mk 61 M 7.5 15 117 117 YES 
33 Rm 43 F 6.2 5 109 109 NO 
34 PK 61 F 8.8 8 108 109 YES 
35 Ch 66 M 8.6 12 117 118 YES 
36 Py 63 M 9.9 6 110 110 NO 
37 Mo 53 M 8.9 20 115 116 YES 
38 Pl 62 M 10.8 7 110 109 NO 
39 Rg 68 M 12.9 11 114 114 NO 
40 Ra 60 M 11.1 11 116 116 YES 
41 Sa 55 F 8.8 7 110 111 YES 
42 Ar 49 M 9.7 9 111 111 NO 
43 Ba 67 M 10.2 6 109 108 NO 
44 Ch 59 M 12.2 2 106 107 YES 
45 Ra 60 F 11.5 4 107 108 NO 
46 Vl 57 F 7.6 1 103 104 NO 
47 Ma 66 M 6.9 12 112 112 YES 
48 Ng 50 M 7.9 16 113 114 NO 
49 Gv 66 F 6.5 10 112 111 NO 
50 KA 55 F 9.2 8 110 109 NO 
 
  
 CONTROLS 
S.NO 
PATIENTS 
NAME 
AGE SEX RIGHTP100 LEFT P100 
1 Is 58 M 100 101 
2 Ra 60 M 99 99 
3 Um 50 F 100 100 
4 Ka 51 F 102 101 
5 Em 56 M 100 101 
6 Ka 55 F 101 101 
7 Gv 62 M 103 102 
8 Ng 64 M 102 102 
9 Ra 51 M 104 103 
10 Ch 42 M 98 99 
11 Pl 53 M 101 101 
12 mo 60 F 103 102 
13 Ph 53 F 98 99 
14 Su 57 M 103 102 
15 Sm 65 F 102 102 
16 Vl 61 F 104 103 
17 Gv 50 F 100 101 
18 Rd 60 F 103 103 
19 Rg 64 M 104 103 
20 Ka 60 M 102 103 
21 Jl 70 M 101 102 
22 Sd 70 F 99 100 
23 Ar 52 F 106 105 
24 ml 65 M 104 103 
 25 am 50 F 98 99 
26 fa 60 M 99 100 
27 ve 66 F 103 103 
28 ch 57 M 104 104 
29 py 60 M 100 101 
30 mo 66 M 102 103 
31 pl 53 F 100 101 
32 rg 61 M 103 102 
33 ra 43 F 99 100 
34 sa 61 F 101 101 
35 ar 66 M 104 103 
36 ba 63 M 102 101 
37 ch 53 M 100 99 
38 ra 62 M 101 101 
39 vl 68 M 99 100 
40 ma 60 M 103 102 
41 ng 55 F 99 98 
42 gv 49 M 100 99 
43 dh 67 M 101 100 
44 ku 59 M 102 100 
45 po 60 F 99 100 
46 am 57 F 101 101 
47 fa 66 M 102 102 
48 ka 50 M 101 101 
49 ve 66 F 103 102 
50 sg 55 F 102 101 
 
